Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate - GBI Research Reports

Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate

Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate - GBI Research Reports
Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate
Published Oct 15, 2011
223 pages — Published Oct 15, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research, Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate, which provides insights into anti-inflammatory therapeutics revenue forecasts until 2017. The report also examines the global anti-inflammatory treatment usage patterns. In addition, the geographical distribution of anti-inflammatory therapies across the US, the top five countries in Europe, and Japan is also provided in the report. The report also includes insights into the anti-inflammatory R&D pipeline. The report provides an in-depth analysis of the top seven inflammatory therapeutic indications, which are respiratory diseases, arthritis, multiple sclerosis, psoriasis, spondyloarthropathies, inflammatory bowel disease and gout. Furthermore, it also includes the market forecasts and treatment usage patterns of these seven therapeutic indications. The report also explores the competitive landscape, including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving anti-inflammatory treatments is also presented.

The in-depth analysis of the report is based on proprietary databases, primary and secondary research, and in-house analysis by the GBI Research team of experts.

GBI Research analysis showed that the global inflammatory therapeutics market was estimated at $57.8 billion in 2010, representing a cumulative annual growth rate of 7.6% between 2002 and 2010. GBI Research forecasts that the market will grow at a Compound Annual Growth Rate (CAGR) of 5.8% between 2010 and 2017, to record a sales value of $85.9 billion. The patent expiry of some major drugs by 2017 is expected to make way for the entry of generics, whereas this impact will be reversed by a number of strong pipeline molecules.

GBI Research has segmented each section of the anti-inflammatory therapeutics market into branded and generics, and estimates the global inflammatory therapeutics to gain 73.1% of revenue from the branded market, whereas 26.9% was achieved from the generics market in 2010. Due to the presence of a strong pipeline portfolio for anti-inflammatories, the branded share is forecast to increase to 78.6% in 2017, and the generics market will decrease to 21.4%.

GBI Research analysis shows that the R&D pipeline for anti-inflammatory therapeutics is strong. Many of the major pharmaceutical companies such as Abbott, Amgen Inc., Johnson & Johnson, GlaxoSmithKline, AstraZeneca, Merck, Pfizer, Eli Lilly, Boehringer Ingelheim and Sanofi are either entering or expanding into the market. They are collaborating with or acquiring small and medium-sized enterprise (SME) pharmaceuticals, which have promising anti-inflammatory drugs in their pipeline. Currently, more than 1,000 molecules are in R&D, with 12% of them in Phase III, 36% in Phase II, 15% in Phase I, 29% in preclinical stage, and 7% in discovery phase. This indicates that anti-inflammatory R&D will be very active for at least the next seven to eight years. The main factor that is driving the big pharmaceutical companies towards the inflammatory therapeutics market is the large patient base. Respiratory diseases and arthritis continue to be some of the most common diseases and are among the leading causes behind major chronic disabilities in the workforce.

Scope

- Data and analysis on the inflammatory therapeutics market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the inflammatory therapeutics market from 2002 to 2010, with forecasts to 2017.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annua

  
Source:
Document ID
GBIHC100MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents39
  List of Tables73
  List of Figures102
Anti-Inflammatory Therapeutics Market to 2017: Introduction122
  GBI Research Report Guidance131
Anti-Inflammatory Therapeutics Market to 2017: Market Overview145
  Introduction141
    Revenue141
    Branded Vs Generics151
    Annual Cost of Treatment161
    Treatment Usage Pattern171
      Diseased Population181
      Treatment Seeking Population181
      Diagnosed Population181
      Prescription Population181
Anti-Inflammatory Therapeutics Market to 2017: Geographical Landscape1917
  Revenue Analysis by Geography192
  The US211
    Revenue211
    Annual Cost of Treatment221
    Treatment Usage Patterns231
      Diseased Population241
      Treatment Seeking Population241
      Diagnosis Population241
      Prescription Population251
  Top Five Countries of Europe251
    Revenue253
    Annual Cost of Treatment282
    Treatment Usage Patterns301
      Diseased Population311
      Treatment Seeking Population311
      Diagnosis Population311
      Prescription Population311
  Japan321
    Revenue321
    Annual Cost of Treatment331
    Treatment Usage Patterns341
      Diseased Population351
      Treatment Seeking Population351
      Diagnosis Population351
      Prescription Population351
Anti-Inflammatory Therapeutics Market to 2017: Therapeutic Landscape3663
  Respiratory Diseases361
    Introduction361
    Revenue362
      Revenue by Country381
      Branded vs. Generics391
    Annual Cost of Treatment401
    Treatment Usage Pattern411
      Diseased Population421
      Treatment Seeking Population421
      Diagnosed Population421
      Prescription Population421
  Drivers and Barriers the Respiratory Therapeutics Market431
    Drivers for Respiratory Therapeutics Market431
      Steady Increase in the Smoking Population431
      Stable Increase in Incidence Rates for Respiratory Diseases441
      Increase in Awareness Levels of Disease Progression and Etiology441
    Barriers for Respiratory Therapeutics Market441
      Patent Expirations and Entry of Generics Pose a Serious Problem for Primary Manufacturers441
      Reimbursement Restrictions on Drug Classes for Respiratory Diseases Restrict the Market Growth441
  Arthritis Therapeutics Market451
    Introduction451
    Revenue451
      Revenue by Country461
      Branded vs. Generics471
    Annual Cost of Treatment481
    Treatment Usage Pattern491
      Diseased Population501
      Treatment Seeking Population501
      Diagnosis Population501
      Prescription Population501
  Drivers and Barriers for Arthritis Therapeutics Market511
    Drivers for Arthritis Therapeutics Market511
      High Incidence and Prevalence Rate511
      Aging Population511
      Increasing Obese Population521
    Barriers for Arthritis Therapeutics Market521
      Low Patient Affordability521
      Availability of Alternative Non-Pharmacological Options521
      Low Treatment Seeking Rate521
  Multiple Sclerosis Therapeutics531
    Introduction532
    Revenue551
      Revenue by Country561
      Branded vs. Generics571
    Annual Cost of Treatment581
    Treatment Usage Pattern591
      Diseased Population601
      Treatment Seeking Population601
      Diagnosis Population601
      Prescription Population601
  Drivers and Barriers for Multiple Sclerosis Therapeutics Market611
    Drivers for Multiple Sclerosis Therapeutics Market611
      High Incidence and Prevalence Rate611
      High Prescription Rate611
      Launch of Several High-Priced Novel Disease-Modifying Therapies621
    Barriers for Multiple Sclerosis Therapeutics Market621
      Patient Affordability and Reimbursement Issues621
      Patent Expiry of Major Drugs is Expected to Cause a Decline in the Market621
      Lower Acceptability Regarding Use of the Medications621
  Psoriasis Therapeutics Market631
    Introduction631
    Revenue641
      Revenue by Country651
      Branded vs. Generics661
    Annual Cost of Treatment671
    Treatment Usage Pattern681
      Diseased Population691
      Treatment Seeking Population691
      Diagnosis Population691
      Prescription Population691
  Drivers and Barriers for Psoriasis Therapeutics Market701
    Drivers for Psoriasis Therapeutics Market701
      Growing Population701
      High Treatment Seeking Behavior701
      Increasing Rate of Prescription711
    Barriers for Psoriasis Therapeutics Market711
      Low Diagnosis Rate711
  Spondyloarthropathies Therapeutics Market711
    Introduction711
    Revenue721
      Revenue by Country731
      Branded vs. Generics742
    Treatment Usage Pattern761
      Diseased Population771
      Treatment Seeking Population771
      Diagnosis Population771
      Prescription Population771
  Drivers and Barriers for Spondyloarthropathies Therapeutics Market781
    Drivers for Spondyloarthropathies Therapeutics Market781
      Increase in Diseased Population781
      New Guidelines Issued to Bring Awareness to Spondyloarthropathies Patients781
    Barriers for Spondyloarthropathies Therapeutics Market791
      Low Diagnosis Rate791
  Inflammatory Bowel Disease791
    Introduction792
    Revenue811
      Revenue by Country821
      Branded vs. Generics831
    Annual Cost of Treatment841
    Treatment Usage Pattern851
      Diseased Population861
      Treatment Seeking Population861
      Diagnosis Population861
      Prescription Population861
  Drivers and Barriers for IBD Therapeutics Market871
    Drivers the IBD Therapeutics Market871
      Approval of Biologics871
      Significant Patient Population871
    Barriers for IBD Therapeutics Market881
      Diagnostic Limitations881
      Complex Etiology881
  Gout Therapeutics Market881
    Introduction883
    Revenue911
      Revenue by Country921
      Branded vs. Generics931
    Annual Cost of Treatment (ACT)941
    Treatment Usage Pattern951
      Diseased Population961
      Treatment Seeking Population961
      Diagnosed Population961
      Prescription Population961
  Drivers and Barriers for Gout Therapeutics Market971
    Drivers for Gout Therapeutics Market981
      Expected Launch of New Drugs will Drive the Gout Therapeutics Market981
      Limited Number of Approved Therapies will Create Concentrated Patient Pools981
      Increasing Prevalence and Diagnosis will Drive the Gout Therapeutics Market981
    Barriers for Gout Therapeutics Market981
      Lower Treatment Seeking Rate Could Prevent the Gout Therapeutics Market from Achieving Higher Growth981
      Low Patient Affordability for Biologics Could Affect the Growth in the Future981
Anti-Inflammatory Therapeutics Market to 2017: Pipeline Analysis9994
  Introduction992
  Anti-Inflammatory Therapeutics Market to 2017 Pipeline Assessment by Clinical Phase of Development1011
    Filed Molecules1011
    Phase III1029
    Phase II11125
    Phase I1369
    Preclinical Phase14528
    Discovery Phase1735
  Anti-Inflammatory Therapeutics Market to 2017 Profiles of Promising Molecules1781
    Indacaterol1781
      Introduction1781
      Mechanism of Action1781
      Clinical Trial Management1791
    BTR-15K1791
      Introduction1791
      Mechanism of Action1791
      Clinical Trial Management1791
    Flutiform1801
      Introduction1801
      Mechanism of Action1801
      Clinical Trial Management1801
    Iguratimod1811
      Introduction1811
      Mechanism of Action1811
      Clinical Trial Management1821
    OHR/AVR1181821
      Introduction1821
      Mechanism of Action1821
      Clinical Trial Management1821
    Simponi1831
      Introduction1831
      Mechanism of Action1831
      Clinical Trial Management1831
    Zushima1841
      Introduction1841
      Mechanism of Action1841
      Clinical Trial Management1841
    Civanex1841
      Introduction1841
      Mechanism of Action1851
      Clinical Trial Management1851
    Naproxcinod1851
      Introduction1851
      Mechanism of Action1851
      Clinical Trial Management1861
    Gilenia1871
      Introduction1871
      Mechanism of Action1871
      Clinical Trial Management1871
    Cladribine1871
      Introduction1871
      Mechanism of Action1871
      Clinical Trial Management1881
    Fampyra1891
      Introduction1891
      Mechanism of Action1891
      Clinical Trial Management1891
    LAS410021891
      Introduction1891
      Mechanism of Action1891
      Clinical Trial Management1901
    BTR-15K1901
      Introduction1901
      Mechanism of Action1901
      Clinical Trial Management1901
    XOMA 0521911
      Introduction1911
      Mechanism of Action1911
      Clinical Trial Management1912
Anti-Inflammatory Therapeutics Market to 2017: Competitive Profiling19311
  Abbott Laboratories1931
    Company Overview1931
    Marketed Products1931
    SWOT Analysis1931
  Amgen Inc.1941
    Company Overview1941
    Marketed Products1941

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate" Oct 15, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Anti-Inflammatory-Therapeutics-Market-to-2017-Respiratory-Diseases-and-Arthritis-Continue-to-Dominate-2115-282>
  
APA:
GBI Research Reports. (2011). Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate Oct 15, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Anti-Inflammatory-Therapeutics-Market-to-2017-Respiratory-Diseases-and-Arthritis-Continue-to-Dominate-2115-282>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.